Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Lucky888 who wrote (36023)	5/13/1999 11:33:00 PM
From: genejockey	Read Replies (2) \| Respond to of 122087

MATX from PR "granting of fast track status does not imply greater or lesser chance of ultimate product approval" Fast track status means nothing in terms of approval. I think people are being mislead here because it is fast track status for review and not a fast track status for approval. Fast track review has more to do with the severity of the disease that the therapy is aimed at... I believe many potential HIV treatments are given fast track review status. This type of runup is hilarious, typically normal reviews take 1 year, fast tracking it cuts it down to 6 months. At least most biotechs that run up -ie. IMCL- are due to positive Phase III results, MATX is hoping to have Phase III results in 2000. Is a 6 month time savings of a products review (which has no bearing on the product's potential approval) worth a nearly 2.5x increase in the share price in one day? Don't think so. ----- Not Howie/Genejockey on Anthony's new site. PS. as with any biotech, the efficacy of this therapy is still a crapshoot. ie. maybe they will be able to deliver more chemo than normal to the local area, but maybe this will result in more normal tissue in that area being killed off which could set off an above normal inflammatory reaction which would cause heightened blood flow to the area resulting in the chemo agent being dissipated and not concentrated to the area.... who knows. In science, the most expected and the least expected results never pan out, it's always something inbetween.

To: Lucky888 who wrote (36023)	5/14/1999 1:19:00 PM
From: AD	Read Replies (2) \| Respond to of 122087

Lucky, MATX is like all the other biotechs that pop huge on a press release about a cancer drug. It was a no brainer short above 7 or 8. Look at the spikes in DRMD ENMD GERN. Clockwork. No way am I staying short, in fact i coverd a little while ago under 5 1/2. but I think it does nothing from here unless another hot press release comes along. I wouldn't want to recommend NITE . It's splitting after the bell. could sell off later today, or monday, just as easily go up. I don't like the risk level long here tho. Not at all. Too much risk for me. Jetups